Validus Pharmaceuticals and Wood Creek Capital Management have acquired the US rights to six product lines from Novartis Pharmaceuticals Corporation (NPC).
The acquired six product lines include Lopressor (metoprolol tartrate USP) excluding Lopressor injection, Lopressor HCT , Lotensin, Lotensin HCT, Parlodel and Methergine.
Post acquisition, Validus will be the exclusive manager for the ex-NPC lines.
Validus CEO James Hunter said, ''Adding these Novartis-developed medications immediately enables Validus to serve additional large and growing markets, particularly Cardiovascular Health.''
Wood Creek CEO Brett Hellerman said, "The acquisition of U.S. rights to these Novartis Pharmaceuticals Corporation products illustrates our belief in and commitment to the mature branded pharmaceuticals market."
Wood Creek Capital Management had acquired the NPC products on 29 August 2012 through US Pharmaceuticals Holdings I.
